MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
出版年份 2020 全文链接
标题
MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 8, Pages 2261
出版商
MDPI AG
发表日期
2020-08-13
DOI
10.3390/cancers12082261
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway
- (2019) Kun Qiao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer
- (2019) Jing Ma et al. Breast Cancer
- The Two Sides of YY1 in Cancer: A Friend and a Foe
- (2019) Sailu Sarvagalla et al. Frontiers in Oncology
- Advances in the systemic treatment of triple-negative breast cancer
- (2018) J.M. Lebert et al. Current Oncology
- Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT
- (2018) Lu Zhao et al. Cell Death & Disease
- ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data
- (2018) Shinya Oki et al. EMBO REPORTS
- STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
- (2018) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- Integrin a6 (CD49f), the microenvironment and cancer stem cells
- (2018) Gabriele D. Bigoni-Ordonez et al. Current Stem Cell Research & Therapy
- Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
- (2017) W. Fraser Symmans et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells
- (2016) Yan Wang et al. GYNECOLOGIC ONCOLOGY
- MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)
- (2016) Lin Zhao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeting the RB-E2F pathway in breast cancer
- (2016) J Johnson et al. ONCOGENE
- Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy
- (2016) Ting Hu et al. Scientific Reports
- miRWalk2.0: a comprehensive atlas of microRNA-target interactions
- (2015) Harsh Dweep et al. NATURE METHODS
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response
- (2015) Alessandra Cataldo et al. Oncotarget
- miR-302b is a potential molecular marker of esophageal squamous cell carcinoma and functions as a tumor suppressor by targeting ErbB4
- (2014) Mingxin Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- MicroRNA-302b-inhibited E2F3 transcription factor is related to all trans retinoic acid-induced glioma cell apoptosis
- (2014) Peng-Hsu Chen et al. JOURNAL OF NEUROCHEMISTRY
- Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?
- (2014) P Meng et al. Cell Death & Disease
- MicroRNAs as therapeutic targets in chemoresistance
- (2013) Michela Garofalo et al. DRUG RESISTANCE UPDATES
- miRNA-302b Suppresses Human Hepatocellular Carcinoma by Targeting AKT2
- (2013) Lumin Wang et al. MOLECULAR CANCER RESEARCH
- MicroRNAs and other non-coding RNAs as targets for anticancer drug development
- (2013) Hui Ling et al. NATURE REVIEWS DRUG DISCOVERY
- Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
- (2013) Loris De Cecco et al. PLoS One
- oPOSSUM-3: Advanced Analysis of Regulatory Motif Over-Representation Across Genes or ChIP-Seq Datasets
- (2013) Andrew T. Kwon et al. G3-Genes Genomes Genetics
- Emerging targeted therapies in triple-negative breast cancer
- (2012) J. Crown et al. ANNALS OF ONCOLOGY
- DAVID-WS: a stateful web service to facilitate gene/protein list analysis
- (2012) X. Jiao et al. BIOINFORMATICS
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
- (2012) H. Thorvaldsdottir et al. BRIEFINGS IN BIOINFORMATICS
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
- (2012) Marilena V. Iorio et al. EMBO Molecular Medicine
- MicroRNA-302 Replacement Therapy Sensitizes Breast Cancer Cells to Ionizing Radiation
- (2012) Zhongxing Liang et al. PHARMACEUTICAL RESEARCH
- Ascl2 Knockdown Results in Tumor Growth Arrest by miRNA-302b-Related Inhibition of Colon Cancer Progenitor Cells
- (2012) Rong Zhu et al. PLoS One
- Integrative genomics viewer
- (2011) James T Robinson et al. NATURE BIOTECHNOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells
- (2009) Jiaqiang Ren et al. Journal of Translational Medicine
- Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt
- (2009) Steffen Durinck et al. Nature Protocols
- PASTAA: identifying transcription factors associated with sets of co-regulated genes
- (2008) Helge G. Roider et al. BIOINFORMATICS
- Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer
- (2008) Mads Thomassen et al. BMC CANCER
- Resistance to chemotherapy: new treatments and novel insights into an old problem
- (2008) S Raguz et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More